ArticleFrontiers in immunology2018
Non-Hematopoietic MLKL Protects Against
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- MAP4Ks drive cell death in response tomBio · 2026Article
- IFI204-STING drives protective innate immunity against gangrenousFrontiers in immunology · 2026Article
- IFI204 RestrictsMicroorganisms · 2025Article
- NLRP3 activation maintains intestinal epithelial barrier and reduces liver injury in alcoholic liver disease mice.Clinical and translational medicine · 2024Article
- GutMicrobiology spectrum · 2024Article
- The pseudokinase MLKL contributes to host defense againstVirulence · 2023Article
- Progress in study on the final executor of necroptosis MLKL and its inhibitors.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- How location and cellular signaling combine to activate the NLRP3 inflammasome.Cellular & molecular immunology · 2022Review
- Mixed lineage kinase-like protein protects againstiScience · 2022Article
- Integrated stress response restricts macrophage necroptosis.Life science alliance · 2022Article
- The Role of the Key Effector of Necroptotic Cell Death, MLKL, in Mouse Models of Disease.Biomolecules · 2021Review
- MLKL inhibits intestinal tumorigenesis by suppressing STAT3 signaling pathway.International journal of biological sciences · 2021Article
- The Role of RIPK1 and RIPK3 in Cardiovascular Disease.International journal of molecular sciences · 2020Review
- Necroptosis in Intestinal Inflammation and Cancer: New Concepts and Therapeutic Perspectives.Biomolecules · 2020Review
- Programmed Cell Death in the Evolutionary Race against Bacterial Virulence Factors.Cold Spring Harbor perspectives in biology · 2020Review
- Plasma Membrane Pores Drive Inflammatory Cell Death.Frontiers in cell and developmental biology · 2020Review
- Pyroptosis versus necroptosis: similarities, differences, and crosstalk.Cell death and differentiation · 2019Review
- Interferons Transcriptionally Up-Regulate MLKL Expression in Cancer Cells.Neoplasia (New York, N.Y.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intestinal mucosal barrier is critical for host defense against pathogens infection. Here, we demonstrate that the mixed lineage kinase-like protein (MLKL), a necroptosis effector, promotes intestinal epithelial barrier function by enhancing inflammasome activation. MLKL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.